It is possible to address this issue further even without more trials. The investigators point out that their analysis is dependent on those studies that have published the number and types of incident cancers. Several have not. Data sets exist, however, from a large number of LDL-lowering trials, including trials of statins, other drugs, diet, and even ileal bypass surgery. If these data sets could be made available for further analyses, we would be in a better position to decide whether there might be a real problem with very low LDL cholesterol levels that should be addressed. Such an analysis could be supported, at relatively low cost, by a neutral source, such as the National Institutes of Health. Funds for such analyses could be awarded on the basis of a peer-reviewed competition with the understanding that the trial data sets would be made available for further study. This would be dependent on the willingness of those in control of these data sets to provide them. They would, of course, require financial and logistical support to do so.